Analysis-Anti-obesity drugs can be boost for food makers, investors say

The growth in demand for appetite suppressing anti-obesity drugs like Novo Nordisk's Wegovy presents opportunities for food manufacturers and the market's initially downbeat reaction may be overdone, investors say. When Walmart said this month that it saw a slight pullback in food consumption when people took the medication, it sparked a sell off in shares of companies including Nestle, the world's biggest packaged food maker. "It feels like quite an overreaction," said Aviva portfolio manager Richard Saldanha.